SAN FRANCISCO, Jan. 6, 2026 -- Braveheart Bio, a late clinical-stage biotechnology company developing novel therapeutics for hypertrophic cardiomyopathy and related conditions, today announced that the company will participate in the 44th Annual J.P. Morgan Healthcare Conference, being held January 12-15 in San Francisco.
Travis Murdoch, M.D., Chief Executive Officer and President of Braveheart Bio, will present an overview of the company on Tuesday, January 13, 2026, at 7:30 a.m. PT / 10:30 a.m. ET. A webcast will be available on the Braveheart website – www.braveheart.bio – and an archived version will be available following the presentation.
About Braveheart Bio
Braveheart Bio is a late clinical-stage biotechnology company developing novel therapeutics for hypertrophic cardiomyopathy and related conditions. The company is backed by experienced life science investors including Andreessen Horowitz (a16z Bio + Health), Forbion, OrbiMed, Enavate Sciences (a platform of Patient Square Capital) and Frazier Life Sciences. Braveheart is advancing BHB-1893 through late-stage clinical development with the goal of establishing a new standard of care. For more information, visit www.braveheart.bio.
Contact
Braveheart-bio@fgsglobal.com
This News is brought to you by Qube Mark, your trusted source for the latest updates and insights in marketing technology. Stay tuned for more groundbreaking innovations in the world of technology.
